
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Betof is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.
Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.
Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.
In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.
Education & Training
- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2016
- Duke University School of MedicineClass of 2013
Certifications & Licensure
- FL State Medical License 2021 - Present
- CA State Medical License 2023 - 2027
- NJ State Medical License 2021 - 2023
- NY State Medical License 2016 - 2023
- OR State Medical License 2021 - 2022
- MA State Medical License 2015 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.Neeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, Achim Jungbluth, Klaus J Busam
Melanoma Research. 2025-06-25 - Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.Elizabeth Buchbinder, Michael T Lotze, Kim A Margolin, Rodabe Amaria, Amod Sarnaik
Journal for Immunotherapy of Cancer. 2025-05-30 - 1 citationsThe Clinical TIL Experience in Melanoma: Past, Present, Future.James W Smithy, Adam J Schoenfeld, Allison Betof Warner
Transplantation and Cellular Therapy. 2025-03-01
Press Mentions
- Failed Phase 3 Trial, Cell Therapy Data Among Top Melanoma News at ASCO 2025June 3rd, 2025
- Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia VeraJune 3rd, 2025
- Big Step Toward Finding the Cure for Multiple Myeloma? “Wonderful” Data at ASCO 2025June 3rd, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: